| CAS: | 174635-69-9 | ||
| 分子式: | C26H24N2O | ||
| 分子量: | 380.48 | ||
| 英文名称: |
| ||
| 用途: | SB 222200是可逆的竞争性人NK受体抑制剂，对hNK-3受体的Ki为4.4 nM，能透过血脑屏障。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||||||||||||||
| S881382 | MACKLIN | SB-222200 | ≥99% | 249元/10mg; 983元/50mg; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||
储存：2-8℃ | |||||||||||||||||||||||||||||||||||||||||||||||||
| S5192 | Sigma-Aldrich | SB 222200 | ≥98% (HPLC), solid | 2625.36元/10 MG; 10281.7元/50 MG; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||
产品说明 应用 The pharmacodynamics profile of SB 222200 enables its use as a tool to study physiological and pathophysiological roles of NK-3 receptor in CNS-modulated behaviors. 包装 10, 50 mg in glass bottle 生化/生理作用 SB 222200 is a 2-phenyl-4-quinolinecarboxamides and a selective, reversible and competitive antagonist of human NK-3 receptor that effectively crosses the blood-brain barrier. It inhibits the NK-3 receptor-induced miosis or pupil constriction in conscious rabbits.1,2 特点和优势 This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. 法律信息 Sold for research purposes under agreement from GlaxoSmithKline 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||
m.cnreagent.com